Despite a lacklustre start to the year, Novartis seems to have overcome its financial slump, reporting operating profits in Q2 that exceeded analyst expectations. The Swiss drugma ...

Halozyme Therapeutics has signed a global partnership and licence agreement with Incyte to assess additional subcutaneous formulations of INCA033989 in patients with mutCALR-expressing MPNs.

The JCA process does not have any influence over pricing and Ipsen must still navigate reimbursement access on a country-by-country basis. Credit: HJBC / Shutterstock.com. The first published joint ...

The therapies’ availability will offer a route to personalised, mutation-specific approaches for types of rare blood cancers.

Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).

UK biotech financing recovery was present in the private markets in Q2 2026 as the sector contends with a tough global funding landscape.

Aptar Pharma has launched a collaborative system-level framework designed to support the development of injectable drug delivery systems.

Bayer's Kerendia will become available to English patients with chronic heart failure with preserved or mildly reduced ejection fraction.

The FDA has issued traditional approval to Novartis for Fabhalta to slow the decline of kidney function in adults with primary IgAN who are at risk of disease progression.

MSD (Merck & Co) has won US Food and Drug Administration (FDA) approval for its cholesterol-lowering pill, marking a significant milestone in the drugmaker’s push to reduce revenue reliance on ...